Comparative Pharmacology
Head-to-head clinical analysis: DYNACIRC versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIRC versus TIAZAC.
DYNACIRC vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker